Smartly Engineered PEGylated Di-Block Nanopolymeric Micelles: Duo Delivery of Isoniazid and Rifampicin Against Mycobacterium tuberculosis
In an attempt to deliver multiple drugs through a nanoparticulate platform, the present study was designed to deliver isoniazid (INH) and rifampicin (RMP) together through conjugation/encapsulation approaches using PEG-PLA (polyethylene glycol-poly-l-lactic acid) polymeric micelles. The objective of this study is to identify the preparation and evaluation of PEGylated polymeric micelles with dual drug delivery of INH and RMP for the effective treatment of tuberculosis (TB). Synthesized PEG-PLA di-block-copolymer was further conjugated to INH-forming PEG-PLA-INH (PPI) conjugate. Separately, these conjugates were loaded with RMP building the rifampicin-loaded PEG-PLA-INH polymeric micelles (PMC). The critical micelle concentration (CMC) for the PEG-PLA copolymer was found to be 8.9 ± 0.96 mg/L, and the size and zeta potential were observed to be 187.9 ± 2.68 nm and − 8.15 ± 1.24 mV (0.251 ± 0.042 pdi), respectively. Percent drug loading of PMC was 16.66 ± 1.52 and 23.07 ± 1.05 with entrapment efficiency of 72.30 ± 3.49 and 78.60 ± 2.67% for RMP and INH, respectively. RBC hemolysis capacity of PMC was significantly less than pure RMP and INH. Microplate Alamar blue assay (MABA) along with microscopy showed that the nanoconstructed PMC were more effective than the drugs, and approximately 8-fold reduction in overall minimum inhibitory concentration (MIC) was observed. The prepared duo drug-loaded nano-engineered polymeric micelles were highly effective against sensitive Mycobacterium tuberculosis strains and found to be less hemolytic in nature. The micelles could be further explored (in the future) for in vivo anti-TB studies to establish further to achieve better treatment for TB.
Key Wordspolymeric micelles (PMC) dual drug delivery isoniazid rifampicin tuberculosis (TB)
The authors would like to acknowledge the financial support received from the Department of Science and Technology and the University Grants Commission, New Delhi, India, to Dr. Umesh Gupta in the form of Rajasthan DST R&D project [File no. 7(3) S & T/R & D/2016/6074]. The authors also would like to acknowledge the Kwality Pharmaceutical Limited, Amritsar, Punjab, India, for providing rifampicin and isoniazid as gift samples.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no competing financial interest.
- 1.World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva: WHO Global Tuberc. Program; 2017.Google Scholar
- 2.Sante ODL. World Health Organization. Communicable Diseases Cluster: Fixed-dose combination tablets for the treatment of tuberculosis. 1999. Google Scholar
- 3.Mitchison DA. Role of individual drug in chemotherapy of tuberculosis. Int J Tuber Lung Dis. 2000;4:790–800.Google Scholar
- 5.World Health Organization. The use of essential drugs, Ninth report of the WHO Expert Committee, Technical Report Series 895. Geneva: World Health Organization; 2000.Google Scholar
- 14.Lesorbre R, Ruffino J, Teyssier L, Achard F, Brefort G. Jaundice occurring during treatment with rifampicin: twelve observations. Rev Tuber Pneumonol. 1969;33:393.Google Scholar
- 29.Dash PN, Murthy L, Chowdhury PN. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm Drug Res. 2010;67:217–23.Google Scholar